bioRxivBiochemistry
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro
H. Liu, P. Wei, Q. Zhang, Z. Chen, K. Aviszus, W. Downing, S. Peterson, L. Reynoso, G. Downey, S. Frankel, J. Kappler, P. Marrack, G. Zhang
Abstract
We generated several versions of the receptor binding domain (RBD) of the Spike protein with mutations existing within newly emerging variants from South Africa and Brazil. We found that the mutant RBD with K417N, E484K, and N501Y exchanges has higher binding affinity to the human receptor compared to the wildtype RBD. This mutated version of RBD also completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Insights on SARS-CoV-2's Mutations for Evading Human Antibodies: Sacrifice and Survival
- Relative Mutant N501Y SARS-CoV-2 Spike Protein RBD Inhibition of Anti-Spike Protein IgG and ACE-2 Binding to Spike Protein Species
M. E. Klegerman, J. D. Cirillo, D. D. McPherson·bioRxiv·Apr 26, 2021
- Neutralization of European, South African, and United States SARS-CoV-2 mutants by a human antibody and antibody domains
- The basis of a more contagious 501Y.V1 variant of SARS-COV-2
G. Zhang, H. Liu, … P. Marrack·bioRxiv·Feb 2, 2021
- Impact of South African 501.V2 Variant on SARS-CoV-2 Spike Infectivity and Neutralization: A Structure-based Computational Assessment
Mary Hongying Cheng, James Krieger, … İvet Bahar·bioRxiv·Jan 10, 2021
- Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N501Y mutations (501Y.V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an escape mutant
G. Nelson, O. Buzko, … P. R. Soon-Shiong·bioRxiv·Jan 13, 2021